Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | PRCP | P42785 | 2/20 | 0.32 |
| ▸ | DRD1 | P21728 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21627622 | 0.73 | HTR2C (0.54) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL2438617 | 0.73 | HTR2A (0.41) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL21627396 | 0.71 | HTR2C (0.51) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL22150019 | 0.68 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5462207 | 0.66 | HTR2C (0.56) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL3089328 | 0.66 | HTR2C (0.56) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL23974178 | 0.64 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4794957 | 0.61 | HTR2C (0.62) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL1520386 | 0.61 | HTR2C (0.62) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL10877517 | 0.61 | HTR2C (0.62) | HTR2CHTR2AHTR2BTAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | HTR2C 2827/4885HTR2A 3772/4885HTR2B 2274/4885 |
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | HTR2C 2827/4885HTR2A 3772/4885HTR2B 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.